Skip to content

Learn

Is BPC-157 legal or FDA approved? (2026 status)

By the Everlon founding team · · How we write and review health content

Quick answer BPC-157 is still not FDA-approved and, as of October 2026, still not on FDA's 503A bulks list, the list of ingredients licensed pharmacies may compound with. What changed is enforcement: under a draft policy published for public comment on October 30, 2026, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding BPC-157 when every one of the policy's conditions is met. The draft is not final, and it is not approval or a permanent authorization.

Where BPC-157 stands, list by list

Most confusion online comes from treating separate lists and policies as one.

List or policyWhat it meansBPC-157, October 2026
FDA-approved drugsReviewed for safety and effectiveness, with approved labelingNot on it
503A bulks list (21 CFR 216.23)Ingredients a licensed pharmacy may compound with when there is no monograph and no approved drug behind themNot on it
Category 1Nominated substances FDA says it does not intend to act against compounders for, while it decidesNot on it
Category 2Nominated substances with significant safety risks identified by FDARemoved April 22, 2026
HHS draft enforcement-discretion policy (October 30, 2026)A draft, not final: HHS says it does not intend to act when every condition is metCovered in the draft, by four routes

The categories and the HHS draft policy are enforcement policies, not law. The bulks list is the rule that counts, and only rulemaking changes it. How the categories work is explained here.

What HHS's October 2026 draft policy says about BPC-157

HHS, the federal department FDA belongs to, has drafted a policy titled "HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." The National Community Pharmacists Association reported it on October 29, 2026, and HHS published it as a draft for comment (Federal Register, FR Doc. 2026-22192; Docket No. HHS-OASH-2026-0496; October 30, 2026), with a two-week comment period; the notice says it is "not binding on HHS or the public." It covers six peptides, and BPC-157 is one of them.

The draft says HHS "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide when all of the policy's conditions are met. For BPC-157 the routes it lists are subcutaneous, intramuscular, oral and topical. A route or form the policy doesn't list isn't covered.

The draft's seven conditions include a valid prescription for an individual patient, a tested ingredient from an FDA-registered manufacturer, BPC-157 as the only active ingredient, the label "This is a compounded drug product. Not for resale.", and serious adverse events reported to FDA's MedWatch program.

As drafted, the policy would run until a final rule decides whether BPC-157 goes on the bulks list, and HHS says it may revisit the policy "in whole or in part" if "a safety signal or product quality issue arises." All six peptides and their routes are here.

Is BPC-157 FDA approved?

No. FDA's July 2026 briefing document says no approved product contains it in any country, and that it is not a component of an FDA-approved drug. HHS's draft policy doesn't change that: compounded drugs, it says, "are not FDA-approved."

FDA describes BPC-157, also called Bepecin or PL-14736, as a peptide reported to be made of 15 amino acids, with no official (USP or NF) monograph. FDA treats its free base and acetate salt as two different substances.

What changed in 2026, and what didn't

None of these steps put BPC-157 on FDA's 503A bulks list.

September 29, 2023: Category 2. FDA placed it on its safety-concern list, citing possible immune reactions, impurities and little or no safety information.

April 22, 2026: off Category 2. FDA removed it, along with eleven other substances, because the nominations had been withdrawn. FDA's guidance says a withdrawal does not reflect an FDA determination about the nomination. It did not move into Category 1, and FDA's safety page still carries its BPC-157 statement.

July 23, 2026: the advisory committee. FDA brought BPC-157 to its Pharmacy Compounding Advisory Committee, evaluated for ulcerative colitis. FDA's own reviewers proposed against adding it to the bulks list. They said it is not well characterized, that little is known about its safety, and that approved treatments for the disease exist. According to news reports (AJMC, July 31, 2026), the committee voted to recommend adding it. FDA has posted no vote record, and its meeting page calls such recommendations non-binding.

October 29 and 30, 2026: HHS's draft policy is reported, then published for comment. It is a draft of enforcement discretion, not a listing: BPC-157's place on the bulks list still waits on a final rule, and the Federal Register showed no proposed rule when last checked for this page, on October 21, 2026.

The law, and where HHS's draft policy fits

Under section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacy may compound with a bulk ingredient only if it meets a USP or NF monograph, is a component of an FDA-approved drug, or is on the bulks list. As of October 2026, BPC-157 meets none of the three: FDA's briefing reports no monograph and no approved drug containing it, and it is not on FDA's bulks list.

Two different things are now in play:

  • Rulemaking, for the long term. Listing BPC-157 still takes a proposed rule, public comments and a final rule. FDA has announced no timetable.
  • Enforcement discretion, proposed. HHS's draft policy, open for public comment and not final, doesn't change the statute or the bulks list, applies only when every condition is met, and may be revisited.

How FDA or a state board would treat a particular pharmacy is a legal question for that pharmacy's counsel.

A prescription vs "research use only"

The policy describes one route: compounding for a named patient on a valid prescription, from a tested ingredient made by an FDA-registered manufacturer, labeled as compounded. A "research use only" product meets none of that. No prescriber reviews your history, no pharmacy prepares it for you, and in August 2026 FDA told five online peptide sellers in writing that the label did not change its view when their websites showed the products were meant for people. The two routes are compared here.

Is this right for me?

Everlon doesn't offer this peptide, so this page can't connect you with a prescription for it. Whether any treatment suits you is a decision for a licensed provider who knows your health history, and the answer may be no.

What you can do today:

  • Ask how each condition is met if a clinic offers it: the prescription, the pharmacy's state license, the manufacturer's FDA registration and certificate of analysis, the route, and the label.
  • Talk to your own doctor about what's prompting the question.
  • Avoid "research use only" products. The risks are set out under Safety information below.
  • Use the sign-up at the end of this page if you want availability news from Everlon. Joining reserves nothing.

How it works

  1. Enter your email below. The form at the end of this page asks for your email address and state, and nothing about your health.
  2. Hear from us only if Everlon offers it. We write about availability and nothing else, and you can unsubscribe anytime.
  3. A licensed provider still decides. Being on the list is not a reservation or a prescription. If Everlon ever offers it, a provider licensed in your state reviews your health history first and can decline.

FAQ

Is BPC-157 legal now? It is still not FDA-approved and, as of October 2026, still not on FDA's bulks list. What changed is that HHS has proposed, in an October 2026 draft policy open for public comment and not final, not to take enforcement action against BPC-157 compounded by a state-licensed pharmacy, federal facility or licensed physician when every condition is met.

Is BPC-157 banned? Not in the sense most people mean. It came off FDA's Category 2 safety-concern list on April 22, 2026, after the nominations were withdrawn, and HHS's draft policy would cover compounding it by four routes under strict conditions. It isn't approved and it isn't on FDA's bulks list.

Did the July 2026 vote make BPC-157 legal? No. News reports say the committee recommended adding it to the bulks list, but the committee only advises and only a final rule adds a substance. HHS's later draft policy is about enforcement, not a listing.

Can a doctor prescribe BPC-157? HHS's draft policy would cover compounding on a valid prescription for an individual patient, by a listed route, when every other condition is met. A prescription doesn't make it FDA-approved, and Everlon doesn't offer it.

Is BPC-157 a controlled substance? No. It does not appear in the federal controlled-substance schedules (21 CFR Part 1308). Separately, FDA's briefing notes that the World Anti-Doping Agency prohibits it in sport.

Is "research use only" BPC-157 covered by the policy? No. The policy describes compounding for a patient on a prescription, from a tested ingredient made by an FDA-registered manufacturer. HHS says the policy responds to research-use-only peptides from foreign manufacturers that pose a safety risk to US patients.

What this means for you

As of October 2026, BPC-157 still isn't on FDA's 503A bulks list, the list of ingredients licensed pharmacies may compound with for patients, and only FDA rulemaking changes that. Until a final rule decides, HHS has proposed, in a draft policy, not to take enforcement action against BPC-157 when its conditions are met; the draft is not final and may change. Compounded medications are not FDA-approved, and products sold online as "research use only" aren't made for people.

HHS's 2026 draft peptide compounding policy, explained covers all six peptides, and the July 2026 FDA peptide vote, explained covers what came before it.

Safety information

BPC-157 is not an FDA-approved drug, so there is no FDA-approved, labeled product to describe here. This is what FDA has said.

  • FDA's safety statement, word for word: "Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans."
  • What that means: immunogenicity is the risk of an immune reaction. The statement records what FDA doesn't know, not a finding of harm, and it is still on FDA's page.
  • Adverse-event reports: FDA's July briefing noted a few reports in its database, such as injection-site reactions, and said it was unclear whether the substance caused them. Reports like these can't show cause either way.
  • "Research use only" products: they are not prepared by a licensed pharmacy for a named patient, no prescriber reviews your health history, and nothing assures you of what is in them, how pure it is or whether it is sterile. FDA's reviewers also noted that sources often don't make clear which form of the substance they mean. Everlon never sells "research use only" products.
  • Compounded medicines in general: compounded medications are not FDA-approved, and that includes anything compounded under HHS's draft policy.

If you have used a product sold under this name and something feels wrong, stop and contact a doctor; you can also report the reaction to FDA's MedWatch program. If this is a medical emergency, call 911.

Sources

  • HHS. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix B; no issue or effective date printed). hhs.gov, accessed 2026-10-29
  • National Community Pharmacists Association (NCPA). Newsroom report on enforcement discretion for compounding six peptides. October 29, 2026 (news report). ncpa.org, accessed 2026-10-29
  • FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of 05/14/2026). fda.gov, accessed 2026-10-21
  • FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (interim categories list), updated May 14, 2026. fda.gov, accessed 2026-10-21
  • FDA. Interim categories list, version updated April 22, 2026 (archived copy). web.archive.org, accessed 2026-10-06
  • FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). fda.gov, accessed 2026-10-21
  • FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (archived copy of April 21, 2026, showing the September 29, 2023 Category 2 date). web.archive.org, accessed 2026-10-06
  • FDA. Guidance for industry: Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (January 2025). fda.gov, accessed 2026-10-06
  • FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (content current as of 08/06/2026). fda.gov, accessed 2026-10-21
  • FDA. FDA Briefing Document: BPC-157 (free base) and BPC-157 acetate. Pharmacy Compounding Advisory Committee, July 23, 2026. fda.gov, accessed 2026-10-06
  • Federal Register. Document search: "BPC-157", all agencies, newest first. federalregister.gov, accessed 2026-10-21 (through the Federal Register's public search API)
  • FDA. Warning Letters (index; the five CDER letters to online peptide sellers dated August 24, 2026, posted September 1, 2026). fda.gov, accessed 2026-10-06
  • 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A. ecfr.gov, accessed 2026-10-06
  • 21 CFR Part 1308, Schedules of controlled substances. ecfr.gov, accessed 2026-10-06
  • AJMC. FDA Panel Backs 6 Peptides for Compounding. July 31, 2026 (news report). ajmc.com, accessed 2026-10-06

Compounded medications are prepared by a state-licensed 503A compounding pharmacy and are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed.

Individual results vary. Treatment is prescribed only when clinically appropriate, and a prescription is never guaranteed. This article is for education and is not a substitute for professional medical advice, diagnosis, or treatment. If this is a medical emergency, call 911.